Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthcare personnel (HCP) who have direct contact with patients, including dentists and other dental health personnel~* Enrolled in Scott \& White Healthcare or Kaiser Permanente health network for at least one month~* Aged 18-64 years for newly enrolled participants~* Aged 18-65 years for participants who were originally enrolled in year one of the study and return for year 2~* Available and willing to participate in study follow-up through the end of the 2019-2020 influenza season (i.e. at least approximately 18 months if enrolled during season 1 or 6 months if enrolled during season 2)~* Received an egg-based standard dose influenza vaccine during the 2018-2019 influenza season (for participants enrolled for the first-time during year two)~Exclusion Criteria:~* Already received an influenza vaccine during the current influenza season~* Previous hypersensitivity reaction to the study vaccines as reported by the subject~* Received any vaccine in the 4 weeks prior to the first study visit or plans to receive a vaccine (other than influenza vaccine provided through the study protocol) in the 4 weeks following the first study visit~* Currently participating in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication), or has received an experimental agent within 1 month prior to enrollment in this study, or expects to receive an experimental agent during participation in this study~* Any condition that the principle investigator (PI) believes may interfere with successful completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Flublok (Recombinant) (Type: ACTIVE_COMPARATOR): Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain
- Flucelvax (Cell-based) (Type: ACTIVE_COMPARATOR): Flucelvax™ Quadrivalent by Seqirus, Inc., 15µg of HA per strain
- Fluarix (Egg-based) (Type: ACTIVE_COMPARATOR): Fluarix® Quadrivalent by GlaxoSmithKlein, 15µg of HA per strain
- Fluzone (Egg-based) (Type: ACTIVE_COMPARATOR): Fluzone® Quadrivalent by Sanofi Pasteur, 15µg of HA per strain
- Fluzone (Egg-based) High-Dose (Type: ACTIVE_COMPARATOR): Fluzone® Trivalent High-Dose by Sanofi Pasteur, 60µg of HA per strain

Based on this trial design, predict the completion outcome and termination type (if applicable).